Clinical trial NCT06035536: Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
Official title: A Multi-Center, Randomized Controlled Clinical Investigation Evaluating Wound Closure With Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Diabetic Foot
Diabetic Foot Ulcer
Foot Ulcer
Chronic Foot Ulcer
Keywords: Extracellular matrix
Regenerative medicine
Leg ulcer
Diabetes Mellitus
Diabetic Angiopathies
Diabetes Complications
Lead sponsor: Aroa Biosurgery Limited
Sponsor class: INDUSTRY
Collaborators: name: Professional Education and Research Institute
First posted: 2023-09-13
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will evaluate the safety and performance of Symphony™ versus Standard of Care (SOC) in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.

Detailed description: About 120 subjects will take part in this study. Subjects with a Wagner Grade 1 or 2 Diabetic Foot Ulcers will be randomized at a ratio of 1:1 to one of the two treatment groups at the time of completion of screening to either Symphony™ treatment or Standard of Care (SOC) treatment groups.

Following initial enrolment, eligible subjects will then undergo:

* A screening phase consisting of 14 days to determine eligibility.
* Eligible subjects will then undergo a treatment phase involving weekly treatment and evaluations for up to 12 weeks.
* Subjects that heal will undergo a follow-up phase that includes 1 visit (Healing Confirmation Visit), 2 weeks from initial healing.
* If the subject does not heal, they will exit at Week 13, End of Study visit.

Both treatment groups will receive accepted routine procedures being part of SOC, including offloading of the DFU (removable cast boot or total contact casting \[TCC\] if the subject's foot is too large for a removable cast boot), appropriate sharp or surgical debridement, and infection management.

In addition to what is noted above, Group 1 will receive a weekly application of Symphony™ and Group 2 will receive SOC comprising of calcium alginate Fibracol dressing. Both Groups will have a silicone non-adherent dressing (MepitelTM or equivalent), a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll, compressive wrap and Coban (Threeflex 3layer or equivalent) applied.

Eligibility criteria: Inclusion Criteria:

* 1. At least 18 years old, inclusive.
* 2. Presence of a DFU, Wagner Grade 1 or 2 (see Appendix B for definitions), extending through the dermis provided it is below the medial aspect of the malleolus.
* 3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
* 4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
* 5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
* 6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable.
* 7. The target ulcer has been offloaded for at least 14 days, prior to TV1.
* 8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
* 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
* 10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed.

Exclusion Criteria:

* 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes
* 2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
* 3. Index ulcer is overtly infected (i.e., purulent drainage)
* 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study
* 5. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1
* 6. History of radiation at the ulcer site (regardless of time since last radiation treatment)
* 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies
* 8. Subjects with a previous diagnosis of HIV or Hepatitis C
* 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment
* 10. Osteomyelitis or bone infection of the affected foot as verified by xray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision)
* 11. Subject is pregnant or breast-feeding
* 12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days
* 13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment
* 14. Presence of acute Charcot Neuroarthropathy to the affected limb
* 15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit

Primary outcomes:
measure: Percentage of index ulcers healed at 12 weeks
timeFrame: 12 weeks
Secondary outcomes:
measure: Time to heal within 12 weeks
timeFrame: 12 weeks
measure: Percentage area reduction at 12 weeks
timeFrame: 12 weeks
measure: Changes in wound quality of life (per W-QoL)
timeFrame: after 12 weeks
measure: Change in pain levels during the clinical investigation
timeFrame: 12 weeks
Other outcomes:
measure: Product wastage (Symphony only)
timeFrame: 12 weeks
measure: Cost to closure (both treatment groups; all wounds, and only closed wounds)
timeFrame: 12 weeks
Locations:
city: Los Angeles
country: United States
facility: LA Foot and Ankle
state: California
city: Los Angeles
country: United States
facility: Clemente Clinical Research Inc.
state: California
city: San Francisco
country: United States
facility: Bay Area Foot Care
state: California
city: Miami
country: United States
facility: Doctor's Research Network
state: Florida
city: Tamarac
country: United States
facility: Barry University Clinical Research
state: Florida
city: Westwood
country: United States
facility: Curalta Foot and Ankle
state: New Jersey
city: Gastonia
country: United States
facility: Foot and Ankle Specialists of the Mid-Atlantic
state: North Carolina
city: Boardman
country: United States
facility: Lower Extremity Institute for Research and Therapy
state: Ohio
city: York
country: United States
facility: Martin Foot and Ankle
state: Pennsylvania
city: Salem
country: United States
facility: Foot and Ankle Specialists of the Mid-Atlantic
state: Virginia
Study officials:
affiliation: Keck School of Medicine
name: David Armstrong, DPM, MD PhD
role: STUDY_CHAIR
References: